Ionis Pharmaceuticals (IONS) to Present Phase 2 Results of donidalorsen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ionis Pharmaceuticals (IONS) PT Lowered to $38 at Stifel, Following Earnings
November 4, 2021 11:45 AM EDTStifel analyst Paul Matteis lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $38.00 (from $42.00) while maintaining a Hold rating.
Analyst comments: "The stock continues to face headwinds after multiple set-backs including the recent miss in the ph3 study of BIIB-partnered... More
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Needham & Company
November 4, 2021 7:28 AM EDTNeedham & Company analyst Chad Messer lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $84.00) while maintaining a Buy rating.
The analyst commented, "IONS reported 3Q21 financial results yesterday, and we spoke w/ mgmt for additional details. Partner BIIB (not rated) previously... More
Ionis Pharmaceuticals (IONS) PT Lowered to $33 at Barclays
November 4, 2021 4:56 AM EDTBarclays analyst Gena Wang lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $33.00 (from $38.00) while maintaining a Equalweight rating.... More
